Cnr1 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Property |
Value |
| Protein Name |
Cannabinoid Receptor 1 (CB1) |
| Gene |
CNR1 |
| UniProt ID |
P21554 |
| PDB ID |
5TGZ, 6N4B |
| Molecular Weight |
53 kDa (un-glycosylated) |
| Subcellular Localization |
Plasma membrane, intracellular vesicles |
| Protein Family |
Class A G protein-coupled receptors (GPCR) |
The CB1 cannabinoid receptor is a typical Class A GPCR with:
- N-terminal extracellular domain: Contains glycosylation sites and ligand-binding region
- Seven transmembrane helices: Form the classic GPCR bundle
- Intracellular loops: Couple to G proteins (Gi/o)
- C-terminal intracellular tail: Contains palmitoylation site and trafficking motifs
¶ Ligand Binding
- Binding pocket located within the transmembrane bundle
- Binds endogenous cannabinoids (anandamide, 2-AG)
- Binds plant-derived cannabinoids (THC)
- Allosteric binding sites identified
- Gi/o protein coupling: Inhibits adenylyl cyclase, reduces cAMP
- Ion channel modulation: Activates inwardly rectifying K+ channels
- ERK/MAPK pathway: Regulates gene expression
- β-arrestin signaling: Mediates some downstream effects
- Modulates neurotransmitter release (glutamate, GABA, dopamine)
- Regulates appetite and energy metabolism
- Involved in memory and learning processes
- Controls pain perception and emotional responses
- Regulates immune function
- Cannabis use disorder: Genetic variants affect addiction risk
- Reward processing: Altered endocannabinoid signaling in addiction
- Therapeutic target: CB1 antagonists (historical: rimonabant)
- Schizophrenia: Altered CB1 signaling contributes to psychosis
- Alzheimer's Disease: Neuroprotective potential of CB1 modulation
- Parkinson's Disease: CB1 changes in basal ganglia
- Huntington's Disease: Progressive CB1 receptor loss
- Multiple System Atrophy: Dysregulated endocannabinoid signaling
| Drug |
Type |
Clinical Use |
| Dronabinol |
Full agonist |
Appetite stimulation, nausea |
| Nabilone |
Synthetic agonist |
Nausea, pain |
| Drug |
Type |
Clinical Use |
| Rimonabant |
CB1 antagonist |
Withdrawn (depression/suicide) |
- Peripherally-restricted CB1 antagonists
- Allosteric modulators
- FAAH inhibitors (increase anandamide)
- Mackie K. (2006). Cannabinoid receptors. Annu Rev Pharmacol Toxicol. PMID:16402910
- Di Marzo V. (2008). Endocannabinoid signaling. Nat Rev Neurosci. PMID:18426499
The study of Cnr1 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Mackie K. (2006). Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol. 46:101-122.
- Di Marzo V. (2008). Endocannabinoid signaling in the brain. Nat Rev Neurosci. 9(11):829-842.
- Piazza PV, et al. (2020). CNR1 and cannabis addiction. Addict Biol. 25(2):e12777.
- Fernández-Ruiz J, et al. (2000). Cannabinoid receptors in neurodegeneration. Pharmacol Ther. 87(2-3):109-125.
- García-González D, et al. (2019). CB1 and Alzheimer's disease. Front Aging Neurosci. 11:35.
- Chiarlone A, et al. (2014). CB1 and Parkinson's disease. Mov Disord. 29(8):997-1005.
- Hurd YL. (2017). Cannabis and the adolescent brain. Nat Rev Neurosci. 18(11):643-659.
- Katona I, et al. (2015). Cannabinoid signaling in the brain. Neuropharmacology. 96(Pt B):151-159.